Family History
441 articles
Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Targeting Mutant KRAS with Immunotherapy
Dr. Beatriz Carreno explains how her team is targeting the KRAS mutation with a pancreatic cancer vaccine to make the immune system work against cancer.
Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Meet the Researcher: Nicolette Juliana Rodriguez, M.D., M.P.H.
Learn more about the research interests of Nicolette Rodriguez, M.D., M.P.H., one of the young investigators Let’s Win sponsored at AACR.
ASCO 2023: Pancreatic Cancer Research Update
The pancreatic cancer research reports from ASCO 2023 focused on different chemotherapy combinations, including immunotherapy.
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
A Look Back at Research in 2024
Research in 2024 focused on personally tailored treatments, countering the most difficult effects of pancreatic cancer, and clinical trials.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
Precursors to Pancreatic Cancer: Are There Any Signs to Watch Out For?
Dr. Venkata Akshintala outlines some of the precursors to pancreatic cancer that people should look out for.